[A new approach to etiotropic therapy ARVI in children].
A U SabitovO P KovtunE V EsaulenkoP V SorokinPublished in: Terapevticheskii arkhiv (2022)
As a result of the conducted clinical study, the high efficacy, safety and good tolerability of the drug riamilovir in the treatment of children aged 12-17 years with a diagnosis of ARVI was established. It is recommended to use the drug riamilovir in clinical practice as an etiotropic therapy in children aged 12-17 years with a diagnosis of ARVI due to its high efficacy and safety.